Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T cell (Treg) therapy to treat myelofibrosis, a rare blood cancer.
Zai Lab has received approval from China’s National Medical Products Administration (NMPA) for the supplemental new drug application (sNDA) for Augtyro (repotrectinib) to treat adult patients with solid tumours harbouring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV).
Insilico Medicine has entered a multi-year research and development (R&D) collaboration with Servier, worth up to $888m, to develop and discover new oncology therapies.
MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem cell therapy for moderate to severe knee osteoarthritis, in Japan.
Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab), in Canada and the US.
New York City-based tech company Inductive Bio has secured up to $21m from the US Advanced Research Projects Agency for Health (ARPA-H) to lead the development of AI drug toxicity prediction models, aimed at improving drug safety assessment and minimising reliance on animal testing.
Agilent Technologies has expanded its collaboration with Monash University Malaysia (MUM) for the establishment of the MUM Proteomics & Metabolomics Platform (MUMPMP)-Agilent BioDiscovery Hub.
Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for the expanded use of Jaypirca (pirtobrutinib) tablets, in 100mg and 50mg doses, to treat adults with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
AGC Biologics is set to expand its Cell Line Development Centre of Excellence through a partnership with ATUM for integrating the Leap-In transposase expression platform into its services.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.